Press releases
-
Korro Bio and Genevant Sciences Enter into Collaboration Agreement to Develop RNA Editing Therapeutic for Alpha-1 Antitrypsin Deficiency
-
Korro Bio Appoints Dr. Steve Colletti as Chief Scientific Officer
-
Korro Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
In the news
-
Korro Bio Raises $116 Million for RNA Editing Program
-
Korro Bio sings to the tune of $116M for its OPERA RNA editing program
-
RNA-editing startup to double headcount with $116M in new VC
Publications
-
Development of a selection assay for small guide RNAs that drive efficient site-directed RNA editing